11/02 Taiwan BIO Weekly
2026-11-02 |
| Taiwan BIO Weekly |
| PET Pharm Biotech to Become Taiwan's First Publicly Listed Radiopharmaceutical Manufacturer 29 October, 2026 PET Pharm Biotech (TW: 7762) secured approval for its Taiwan OTC listing on the 28th of October and expects to debut by late December 2026 as Taiwan's first publicly listed radiopharmaceutical company. Specializing in diagnostic and therapeutic radiopharmaceuticals, the company focuses on precision medicine, neurodegenerative diseases, cancer diagnostics, and targeted radionuclide therapies. More... (in Chinese) |
| PharmaEngine Posts Nine-Month EPS of NT$2.87, Driven by Onivyde and New Drug Development 29 October, 2026 PharmaEngine (TW: 4162) reported net profit of NT$413 million and earnings per share (EPS) of NT$2.87 for the first nine months, reflecting stable profitability. With its pancreatic cancer drug ONIVYDE expanding across European and Asian markets and two oncology drug candidates, PEP07 and PEP08, advancing through clinical trials, the company is pursuing a dual growth strategy driven by royalty income from existing products and innovative drug development. More... (in Chinese) |
| Taiwan Advance Bio-Pharmaceutical Revenue Rises Over 30% on Growing Drug Testing Demand 29 October, 2026 Taiwan Advance Bio-Pharmaceutical (TW: 4186) reported drug testing revenue of NT$95.24 million for the first nine months of 2026, up 33.41% year-on-year, while September revenue rose 14.22%. Since acquiring technology from the Development Center for Biotechnology (DCB) in 2000, the company has focused on diagnostic reagents, antibody production, and biotechnology applications. Its operations include monoclonal and polyclonal antibody production, drug identification, rapid testing, enzyme immunoassay platforms, urine drug screening, and food safety testing. More... (in Chinese) |
| Genomics BioSci & Tech Partners with Alamar to Introduce Protein Detection Platform Targeting Alzheimer's Research 28 October, 2026 Genomics BioSci & Tech (TW: 4195) announced the installation of a high-sensitivity protein detection platform in Taiwan through its partnership with US-headquartered Alamar Biosciences, featuring NULISA technology and the automated ARGO HT system. Initially targeting Alzheimer's disease research, the collaboration aims to advance proteomics applications in Taiwan. The company also plans to expand beyond gene sequencing into proteomics, multi-omics, and translational medicine, serving research institutions, medical centers, and biotech and pharmaceutical companies. More... (in Chinese) |
| AnnJi Pharmaceutical Receives Positive Feedback on Keloid Drug, Plans Phase I Clinical Trial 28 October, 2026 AnnJi Pharmaceutical (TW: 7754) announced on the 27th of October that it has received positive feedback from the US FDA on its IND application for AJ305, a highly selective HDAC6 inhibitor, allowing it to proceed with a Phase I clinical trial in patients with keloids. The company also plans to seek clinical trial approval from the Taiwan FDA. Keloids are a chronic skin condition characterized by excessive scar tissue growth, often causing pain, itching, and cosmetic concerns. The global keloid treatment market is projected to reach US$5.4 billion by 2030. More... (in Chinese) |
| TTY Biopharm Expects Strong Growth in 2027, Driven by Three Key Businesses 28 October, 2026 TTY Biopharm (TW: 4105) reported September net profit of NT$268 million, with EPS of NT$1.08, bringing its nine-month EPS to NT$5.40. In an announcement, the company expects three growth drivers to boost performance next year: NHI reimbursement for its domestically developed third-generation EGFR-targeted lung cancer drug, overseas expansion of its liposomal antibiotic Lipo-AB, and the launch of a new freeze-drying production line at its Liudu plant in the fourth quarter. More... (in Chinese) |
| Vetnostrum Animal Health Leverages Two Growth Drivers to Expand in ASEAN 28 October, 2026 Vetnostrum Animal Health (TW: 6936) plans to establish a subsidiary in Singapore following its announcement in July of a NT$718 million investment in Vietnam, gradually building an international production and operating network. With a rising share of high-margin products and growing demand for companion animal medicines and non-medicated feed additives, analysts are optimistic about the company's Southeast Asian expansion strategy and expect its business to reach new highs in 2027. More... (in Chinese) |
| Taiwan and US Medical Leaders Unite in Los Angeles to Explore the Future of Smart Medicine 28 October, 2026 According to Numbeo's latest 2026 Health Care Index, Taiwan has once again ranked #1 in the world with a high score of 87.1, marking its eighth consecutive year at the top. Standing behind this remarkable achievement is a dedicated group of Taiwanese medical pioneers who never stop innovating and breaking new ground. More... |
| Global Licensing Boom Fuels Partnership Opportunities for Taiwan's Biotech Industry 27 October, 2026 International licensing activity in the biotech sector is picking up again. TLC BioSciences (TW: 7924) is set to sign a licensing agreement with Japan's Seikagaku Corporation on the 29th of October for its long-acting pain treatment TLC599, in a deal worth up to US$203 million, setting a record for Taiwan-Japan biotech licensing deals. Analysts are also optimistic about five companies: TAHO Pharmaceuticals (TW: 6467), Handa Pharmaceuticals (TW: 6620), BRIM Biotechnology (TW: 6885), HanchorBio (TW: 7827), and TaiMed Biologics (TW: 4147), which could secure further international licensing deals and strategic partnerships as their drug candidates advance through clinical development, regulatory approval, and commercialization. More... |
| Rewiring immunity: How a Taiwan biotech is turning antibodies into an HIV lifesaver 27 October, 2026 As of 2025, over 41 million people were living with human immunodeficiency virus (HIV) worldwide. Over 1 million of those came from infections that same year. Acquired immunodeficiency syndrome (AIDS)-related illnesses accounted for 570,000 deaths last year, adding to 44 million total fatalities since the beginning of the epidemic. More... |
| How Bold New Leadership Is Setting a Course for Progress at MSD Taiwan Sponsored interview 27 October, 2026 For executives of multinationals, coming to Taiwan for the first time can often be an eye-opening experience. The country is renowned for its safety and convenience, as well as a friendly and welcoming environment for newcomers. More... |
| ========================================= |
| Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter. |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2027 (27-31 July, 2027) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |